C
Canada House Cannabis Group Inc
CNSX:CHV
Canada House Cannabis Group Inc
CNSX:CHV
Price:
0.55
CAD
Market Cap:
CA$25.1m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Canada House Cannabis Group Inc
CNSX:CHV
|
CA |
|
H
|
Haloni Jane PT Tbk
IDX:HALO
|
ID |
|
Orchestra Holdings Inc
TSE:6533
|
JP |
|
S
|
Sonetel AB (publ)
STO:SONE
|
SE |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of CHV.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CHV
Multiples-Based Value
Not Available
Multiples Across Competitors
CHV Competitors Multiples
Canada House Cannabis Group Inc Competitors
Canada House Cannabis Group Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
C
|
Canada House Cannabis Group Inc
CNSX:CHV
|
25.4m CAD | 0.9 | -28.8 | 5.8 | 11.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
871.6B USD | 13.1 | 41.3 | 27.9 | 29.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.1B USD | 6.1 | 21.3 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.7 | 11.6 | 13.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.4B GBP | 5.2 | 29.7 | 16.4 | 23.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296.9B USD | 4.5 | 16 | 9.9 | 12.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
230.8B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 11 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.1B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89.3B GBP | 2.7 | 15.2 | 8.2 | 10.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
